Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 12:31 AM
Ignite Modification Date:
2025-12-25 @ 12:31 AM
NCT ID:
NCT02031367
Eligibility Criteria:
Inclusion Criteria:
* Males or females ages 18 and older.
* Active duty soldiers and military health care beneficiaries.
* Have lateral hip pain in the region of the greater trochanter for at least 6 weeks and have done physical therapy.
* Reproducible pain on palpation of the greater trochanteric region.
* Tendinopathy diagnosed with ultrasound. The criteria is as follows: a well-defined hypoechoic area with partial tear or complete tendon rupture that is suggestive of a tendon tear. A hyperechoic intratendinous area with posterior acoustic shadowing suggestive of a calcification, or both
Exclusion Criteria:
* Received corticosteroid for the condition in last 6 months.
* History of surgery in affected hip.
* Allergy to Lidocaine.
* Allergy to Corticosteroid.
* Unavailable for follow up by telephone for 12 months after initial injection.
* Patients with broken skin or skin infections immediately overlying the area to be injected.
* Patients with complete tears of the gluteal tendons with retraction of the muscle and or tendon, as determined by ultrasound.
* If they are pregnant or planning on becoming pregnant during the study time. Because of the physiologic changes during pregnancy we cannot predict how Corticosteroids will affect the mother and the infant. Also, this will increase stress to an already immunocompromised state.
* Have not attended formal physical therapy
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT02031367
Study Brief:
Protocol Section:
NCT02031367